About 30 results found for searched term "Tyrosine kinase-IN-6" (0.133 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M43486 | Tyrosine kinase-IN-6 | c-Met |
| Tyrosine kinase-IN-6 is a potent and promising RON splice variants inhibitor with anti-cancer and o?antineoplastic effects. | ||
| M1643 | AEE788 | EGFR/HER2 |
| NVP-AEE 788 | ||
| AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1. | ||
| M1743 | X-376 | ALK |
| X-376 is a potent and highly specific ALK small molecule tyrosine kinase inhibitor with IC50 of 0.61 nM. | ||
| M1784 | Icotinib | EGFR/HER2 |
| BPI-2009H | ||
| Icotinib (BPI-2009H) is a potent and novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC50 of 5 nM. Iconitib inhibits the proliferation of A431 and BGC-823 A549, H460 and KB cell lines with IC50s of 1, 4.06, 12.16, 16.08, 40.71 μM. | ||
| M1994 | Telatinib | VEGFR/PDGFR |
| BAY 57-9352 | ||
| Telatinib (BAY 57-9352) is an orally active small-molecule tyrosine kinase inhibitor of VEGFR2, VEGFR3 and PDGFRβ with IC50 of 6 nM, 4 nM and 15 nM, respectively. | ||
| M4867 | Pexidartinib | c-Kit |
| PLX3397; Turalio | ||
| Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. | ||
| M4870 | Cerdulatinib | JAK |
| PRT062070, PRT2070 | ||
| Cerdulatinib (PRT-062070, PRT2070) is an orally active multi-target tyrosine kinase inhibitor with IC50s of JAK1/JAK2/JAK3/TYK2 and Syk 12 nM/6 nM/8 nM/0.5 nM and 32 nM, respectively. It was also able to inhibit the other 19 kinases tested, all with IC50 below 200 nM. | ||
| M5280 | XMD8-87 | Tyrosinase |
| ACK1-B19 | ||
| XMD8-87 is a novel tyrosine kinase nonreceptor 2(TNK2) inhibitor with IC50s of 38 nmol/L and 113 nmol/L for the D163E and R806Q mutations. | ||
| M5281 | XMD16-5 | Tyrosinase |
| XMD16-5 is a novel tyrosine kinase nonreceptor 2(TNK2) inhibitor with IC50s of 16 nmol/L and 77 nmol/L for the D163E and R806Q mutations. | ||
| M7536 | BMS-935177 | BTK |
| BMS-935177 is a potent, reversible Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 value of 2.8 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective. | ||
| M7630 | Butein | PDE |
| 2’,3,4,4’-tetrahydroxy Chalcone | ||
| Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator. | ||
| M9626 | Sitravatinib | VEGFR/PDGFR |
| MGCD516; MG516 | ||
| Sitravatinib (MGCD516) is an orally active receptor tyrosine kinase (RTK) inhibitor. Inhibition of Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, and TRKB at 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, respectively. 29 nM, 5 nM and 9 nM. Sitravatinib alone has a potent antitumor effect and enhances pD-1 blockade activity by promoting the antitumor immune microenvironment. | ||
| M10329 | Ningetinib | VEGFR/PDGFR |
| CT-053; DE-120; CT053PTSA | ||
| Ningetinib is a potent, orally bioavailable tyrosine kinase inhibitor for Axl, VEGFR2 and c-Met with IC50 values of <1.0, 1.9 and 6.7 nM, respectively. | ||
| M11240 | Zanzalintinib | TAM Receptor |
| XL092; JUN04542 | ||
| Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multireceptor tyrosine kinases (RTKs), including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM and 7.2 nM in cell analysis, respectively. XL092 has antitumor activity. | ||
| M14880 | BMX-IN-1 | BTK |
| BMX kinase inhibitor | ||
| BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity. | ||
| M20833 | Vodobatinib (K0706) | Src-bcr-Abl |
| SCO-088, SUN K706, SUN-K0706 | ||
| Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively. | ||
| M20877 | Toceranib phosphate | VEGFR/PDGFR |
| SU11654 | ||
| Toceranib phosphate is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. | ||
| M21409 | FN-1501 | CDK |
| LT-171-861 | ||
| FN-1501 is a potent inhibitor of Fms-like receptor tyrosine kinase 3 (FLT3) and cyclin-dependent kinase (CDK), and the IC50 for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3 with IC50s of 2.47, 0.85, 1.96 and 0.28 nM, respectively. | ||
| M21588 | GSK2646264 | Syk |
| GSK2646264 is a potent and selective splenic tyrosine kinase (Syk) inhibitor with a pIC50 value of 7.1. GSK2646264 also inhibited other kinases, with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 for LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 penetrates into the epidermis and dermis of the skin. | ||
| M25091 | Mipasetamab | Others |
| Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity. | ||
| M28071 | S116836 | Src-bcr-Abl |
| S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies. | ||
| M28158 | TAK-659 | Syk |
| Mivavotinib | ||
| TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL). | ||
| M28324 | Ningetinib Tosylate | TAM Receptor |
| Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. | ||
| M28913 | NTRC 0066-0 | Others |
| NTRC 0066-0 is a selective threonine tyrosine kinase (TTK) inhibitor (IC50=0.9 nM). NTRC 0066-0 can be used for the research of cancer. | ||
| M29480 | BGB-8035 | BTK |
| BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research. | ||
| M29909 | SU11652 | VEGFR/PDGFR |
| SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research. | ||
| M30289 | DB07107 | Src-bcr-Abl |
| DB07107 is a potent agent resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent Akt1 inhibitor with an IC50 value of 360 nM. | ||
| M30952 | Lck inhibitor 2 | Src-bcr-Abl |
| Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively IC50 Value: 13 nM(Lck) [1] Target: Src family kinase Lck inhibitor 2(Compound 9) inhibited 48 kinases with %control < 1 (33 of them tyrosine kinases, almost half of the 71 tyrosine kinases in the panel). A further 27 kinases were bound with %control < 10. Kd values for 16 kinases were determined and found to be below 100 nM. These included TXK (10 nM). | ||
| M40621 | DZD1516 | EGFR/HER2 |
| DZD1516 is an orally active, potent, reversible, and selective HER2 small molecule tyrosine kinase inhibitors (TKIs) with an IC50 value of 0.56 nM, which completely penetrates the blood-brain barrier. It can be used in studies related to HER2-positive breast cancer. | ||
| M43473 | Cinsebrutinib | BTK |
| Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
